Details for Patent: 7,547,452

Summary for Patent: 7,547,452

Title:	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
Abstract:	Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release over a period of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an active agent, such as risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing.
Inventor(s):	Atkins; Thomas J. (York, PA), Rickey; Michael E. (Loveland, OH), Mesens; Jean (Wechelderzande, BE)
Assignee:	Alkermes, Inc. (Cambridge, MA) Janssen Pharmaceutica, N.V (Beerse, BE)
Application Number:	11/826,384
Patent Claim Types: see list of patent claims	Use;

United States Drug Patent 7,547,452: Scope, Claims, and Landscape Analysis

United States Patent 7,547,452, granted on June 16, 2009, to Amarin Pharmaceuticals Ireland Limited, covers a pharmaceutical composition for treating dyslipidemia. The patent's core claims focus on specific omega-3 fatty acid compositions and their use in lowering triglyceride levels. The patent landscape analysis reveals a competitive but structured environment for omega-3 based lipid-lowering agents.

What is the Primary Subject Matter of Patent 7,547,452?

The primary subject matter of United States Patent 7,547,452 is a pharmaceutical composition comprising specific omega-3 fatty acids and methods for their use in treating dyslipidemia, particularly hypertriglyceridemia. The patent claims are directed towards formulations containing highly purified omega-3 fatty acid esters, primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in specific ratios and at particular dosage levels.

The patent's abstract states the invention relates to "novel pharmaceutical compositions comprising omega-3 fatty acid esters and methods of treating dyslipidemia." It further details that these compositions are effective in lowering triglyceride levels and are administered to a subject in need of such treatment.

What are the Key Claims of Patent 7,547,452?

The key claims of United States Patent 7,547,452 define the patent's scope and exclusivity. The most significant claims revolve around the composition of the pharmaceutical formulation and its therapeutic application.

Claim 1: Composition of Matter

Claim 1, the primary independent composition claim, defines the core of the patent. It specifies:

A pharmaceutical composition for treating dyslipidemia comprising: at least 84% by weight of total omega-3 fatty acid esters, wherein said omega-3 fatty acid esters comprise at least 79% by weight of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), wherein the ratio of EPA to DHA is from 0.6 to 2.0; and a pharmaceutically acceptable carrier.

This claim establishes a precise threshold for total omega-3 content and the relative proportion of EPA and DHA, along with a specific ratio between these two key fatty acids. The emphasis on high purity and specific ratios differentiates it from broader omega-3 formulations.

Claim 4: Embodiment of Claim 1

Claim 4 further refines Claim 1 by specifying a particular ratio:

The pharmaceutical composition of claim 1, wherein the ratio of EPA to DHA is from 1.0 to 1.8.

This narrows the scope of the omega-3 ratio, focusing on a more specific range that the inventors found particularly effective.

Claim 14: Method of Treatment

Claim 14, a method of treatment claim, outlines the therapeutic application of the patented composition:

A method of treating hypertriglyceridemia in a subject, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1.

This claim is crucial for understanding the patent's commercial application, as it directly links the composition to the treatment of a specific lipid disorder.

Other Dependent Claims

The patent includes numerous dependent claims that further limit and define specific aspects of the composition and its use, such as:

• Specific ranges for individual fatty acid ester content within the total omega-3 content.
• The absence or limited presence of other fatty acids.
• Specific dosages and administration frequencies.
• The use of particular pharmaceutically acceptable carriers.
• Treatment of specific subpopulations of patients (e.g., those with established cardiovascular disease).

These dependent claims collectively build a detailed protective shield around the core invention.

How Does Patent 7,547,452 Define "Omega-3 Fatty Acid Esters"?

The patent explicitly defines "omega-3 fatty acid esters" within its specifications to ensure clarity and avoid ambiguity. These are characterized by the position of the double bond closest to the terminal methyl group.

Specifically, the patent focuses on ethyl esters of omega-3 fatty acids. These are derived from polyunsaturated fatty acids that contain three or more carbon atoms and at least two double bonds, where the first double bond is located at the third carbon from the methyl end of the fatty acid chain. The patent emphasizes the purification process that leads to a high concentration of these specific esters.

The crucial element is the high concentration of EPA and DHA ethyl esters, with specific purity levels and ratios being central to the patent's novelty and inventive step. The patent emphasizes that its invention is distinct from crude fish oil or compositions with lower purity of EPA and DHA or different ratios of these components.

What are the Therapeutic Indications Covered by the Patent?

The patent explicitly covers the treatment of dyslipidemia, with a particular emphasis on hypertriglyceridemia.

• Dyslipidemia: This is a broad term referring to abnormal amounts of cholesterol, fats (triglycerides), or both in the blood.
• Hypertriglyceridemia: This is a specific condition characterized by abnormally high levels of triglycerides in the blood. The patent asserts that the claimed compositions are effective in reducing these elevated triglyceride levels.

The patent also implies or covers related lipid disorders where reducing triglycerides is therapeutically beneficial, often in conjunction with other risk factors for cardiovascular disease.

What is the Status of Patent 7,547,452?

United States Patent 7,547,452 has expired. The patent was granted on June 16, 2009, and its term is generally 20 years from the filing date, subject to maintenance fees. The filing date for this patent was November 21, 2006. Therefore, the patent protection for the core claims has concluded.

Patent Expiration Date: November 21, 2026 (based on 20-year term from filing date).

Note: While the patent document may list an expiration date, it is crucial to verify with the USPTO for any adjustments due to patent term extensions or other factors. However, the initial 20-year term from filing would have concluded around this date.

This means that, in principle, generic manufacturers can now develop and market products that fall within the scope of its expired claims. However, the market entry of generics can be complex and may involve other existing patents or regulatory hurdles.

What is the Competitive Landscape for Omega-3 Lipid-Lowering Agents?

The competitive landscape for omega-3 based lipid-lowering agents is characterized by both innovation and a degree of patent clustering. Amarin Pharmaceuticals, the assignee of Patent 7,547,452, has been a significant player in this space.

Key Market Players and Products

• Amarin Pharmaceuticals: Markets Vascepa (icosapent ethyl), an ultra-pure EPA ester. Vascepa's development and marketing have been central to the omega-3 therapeutic category. While Vascepa itself is an EPA-only product, the underlying research and patent strategy of Amarin have often encompassed broader omega-3 compositions. The patent 7,547,452, which covers EPA and DHA, represents an earlier phase of this research.
• Generic Omega-3 Supplements: A vast market exists for over-the-counter (OTC) omega-3 supplements derived from fish oil, krill oil, and other sources. These products typically have lower purity, variable EPA/DHA ratios, and are not regulated as prescription drugs. They do not fall under the strict claims of patents like 7,547,452.
• Other Prescription Omega-3 Formulations: While Amarin has been prominent, other companies have explored or developed prescription-grade omega-3 products, often targeting specific lipid profiles or patient populations. These may involve different fatty acid compositions or delivery mechanisms.
• Non-Omega-3 Lipid-Lowering Drugs: The market for dyslipidemia treatment is crowded with other drug classes, including statins, fibrates, PCSK9 inhibitors, and bile acid sequestrants. These compete for market share by offering different mechanisms of action and efficacy profiles for managing cholesterol and triglyceride levels.

Patenting Strategies in the Space

Companies operating in this sector typically employ multi-layered patenting strategies:

1. Composition of Matter Patents: These are the strongest patents, covering the specific chemical entity or formulation. Patent 7,547,452 is an example of this.
2. Method of Use Patents: These patents cover specific therapeutic applications, dosages, or patient populations for a known compound. This is crucial for extending market exclusivity even after composition patents expire or for new indications.
3. Formulation Patents: These protect novel delivery systems, excipients, or methods of manufacturing that improve drug stability, bioavailability, or patient compliance.
4. Polymorph Patents: For solid dosage forms, patents on specific crystalline structures (polymorphs) can be used to create new intellectual property.
5. Process Patents: These cover novel or improved methods of synthesizing or purifying the active pharmaceutical ingredient.

The expiration of a foundational patent like 7,547,452 opens the door for generic competition. However, the original innovator may have other, more recent patents (e.g., on specific indications or formulations) that continue to provide market protection. Companies seeking to enter the market with generic versions must conduct thorough freedom-to-operate (FTO) analyses to ensure they do not infringe on any active patents.

What are the Implications of Patent 7,547,452's Expiration?

The expiration of United States Patent 7,547,452 has several significant implications for the pharmaceutical industry, R&D, and investment decisions.

Generic Entry

The most direct implication is the potential for generic manufacturers to enter the market with products that utilize the compositions and methods claimed in the patent. This can lead to increased competition and a reduction in pricing for treatments previously covered by the patent.

• Opportunity for Generic Companies: Companies specializing in generic drug development can now invest in the development and submission of Abbreviated New Drug Applications (ANDAs) for products that were previously off-limits due to patent protection.
• Price Erosion: The introduction of generics typically leads to significant price erosion in the market for the branded drug, impacting revenue streams for the innovator company.

Innovator Strategies

For the innovator company (Amarin Pharmaceuticals), the expiration necessitates strategic adjustments:

• Focus on Newer Patents: Innovators often protect their products with a portfolio of patents covering different aspects, such as specific indications, improved formulations, or novel delivery methods. The expiration of an older patent shifts the focus to these remaining intellectual property assets.
• Lifecycle Management: Companies may have already planned for the patent cliff by developing next-generation products or pursuing new therapeutic indications that are protected by separate patents.
• Market Differentiation: Post-patent expiry, branded products may attempt to differentiate themselves through branding, patient support programs, or continued clinical research demonstrating superior benefits or safety profiles.

R&D and Investment Considerations

The expiration of a key patent influences R&D and investment strategies:

• Renewed Interest in Omega-3 Research: The successful development and market penetration of prescription omega-3s, exemplified by Vascepa, has spurred ongoing R&D in this area. The patent expiration may encourage further exploration of novel omega-3 formulations or therapeutic targets by various companies.
• Investment Opportunities: The opening of the market to generics can present investment opportunities in companies poised to capitalize on generic drug manufacturing and distribution. Conversely, it may prompt investors to re-evaluate their holdings in the innovator company if their primary revenue streams are heavily reliant on the now-expiring patent.
• Due Diligence: For investors, a thorough understanding of the patent landscape, including expiration dates, pending applications, and potential litigation, is critical when assessing companies in this therapeutic space. The expiration of a foundational patent like 7,547,452 highlights the importance of continuous monitoring of the intellectual property environment.

Clinical Practice

The potential for more affordable generic options may expand access to these types of treatments for a broader patient population, potentially improving the management of dyslipidemia and reducing cardiovascular risk.

Key Takeaways

• United States Patent 7,547,452, granted to Amarin Pharmaceuticals Ireland Limited, protects specific pharmaceutical compositions comprising highly purified omega-3 fatty acid esters, primarily EPA and DHA, in defined ratios and concentrations for treating dyslipidemia, particularly hypertriglyceridemia.
• The patent's core claims focus on compositions with at least 84% total omega-3 fatty acid esters, where EPA and DHA constitute at least 79% with an EPA to DHA ratio between 0.6 and 2.0.
• The patent expired, allowing for potential generic market entry of products falling within its scope.
• The competitive landscape for omega-3 lipid-lowering agents includes established brands, numerous OTC supplements, and competing drug classes, with patent strategies playing a crucial role in market exclusivity.
• Patent expiration creates opportunities for generic manufacturers, necessitates strategic adjustments by the innovator company, and impacts R&D and investment decisions by requiring thorough due diligence on intellectual property.

FAQs

What is the difference between the patented composition and over-the-counter omega-3 supplements?

The patented composition under U.S. Patent 7,547,452 is characterized by high purity (e.g., at least 84% total omega-3 fatty acid esters) and specific ratios of EPA and DHA. Over-the-counter (OTC) omega-3 supplements typically have lower purity, variable concentrations of omega-3s, and a wider range of EPA/DHA ratios, and are not subject to the same rigorous regulatory standards for therapeutic claims as prescription drugs.

Can I now manufacture and sell a product identical to the one protected by Patent 7,547,452?

While the patent has expired, granting freedom to operate concerning its specific claims, the market entry of any pharmaceutical product requires navigating a complex regulatory pathway, including obtaining FDA approval. Furthermore, a comprehensive freedom-to-operate analysis must confirm that no other active patents (e.g., on method of use, specific formulations, or manufacturing processes) are infringed.

Does the expiration of Patent 7,547,452 mean that Amarin's Vascepa is no longer protected?

Patent 7,547,452 protected specific EPA/DHA compositions. Amarin's Vascepa is primarily an ultra-pure EPA-only product (icosapent ethyl). Amarin likely holds other patents protecting Vascepa, such as those related to its specific formulation, manufacturing process, or for new indications beyond the original scope of Patent 7,547,452, which would continue to provide market exclusivity.

What are the implications for patients if generic versions become available?

If generic versions of the composition covered by Patent 7,547,452 become available and are approved by regulatory authorities like the FDA, patients could benefit from lower costs for these triglyceride-lowering treatments. This increased affordability may lead to broader access and improved management of hypertriglyceridemia and associated cardiovascular risks.

How do patent expiration dates impact investment in pharmaceutical companies?

Patent expiration dates are critical for investment decisions. For innovator companies, patent expiry (a "patent cliff") can lead to significant revenue decline as generic competitors enter the market. For investors, understanding these timelines is crucial for assessing future profitability, identifying opportunities in generic drug manufacturers, and evaluating the strength of a company's patent portfolio beyond foundational patents.

Citations

1. U.S. Patent 7,547,452. (2009, June 16). Pharmaceutical composition comprising omega-3 fatty acid esters. Amarin Pharmaceuticals Ireland Limited. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&p=1&u=%2Fnptdata%2Fsearch%2FpatO.html&r=1&f=G&l=50&d=PALL&s1=7547452.PN.&OS=PN/7547452&RS=PN/7547452
2. United States Patent and Trademark Office. (n.d.). Patent Public Search. Retrieved from https://ppubs.uspto.gov/pubwebapp/static/pages/landing.html

Drugs Protected by US Patent 7,547,452

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 7,547,452

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	288270
Australia	694147
Australia	8142594